source
- Taiho and Cullinan’s zipalertinib shows progression‑free survival benefit in Phase 3 NSCLC trialTaiho Pharmaceutical and Cullinan Therapeutics reported that their EGFR inhibitor zipalertinib, combined with chemotherapy, significantly extended progression‑free survival for patients with advanc…
- Avalyn Pharma CEO shares personal moment as company prepares for Nasdaq IPOAvalyn Pharma and Generate Biomedicines executives talked about the long hours and challenges of preparing their companies for an initial public offering. Avalyn CEO Lyn Baranowski highlighted a m…